EGFR inhibitors

Lapatinib (INN), used in the form of lapatinib ditosylate (USAN) (trade names Tykerb and Tyverb) is an orally active drug for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways. It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2)....Wikipedia

Manufacturer's Website: Tykerb

Average retail cost: $1,350/month

Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic. It binds to the epidermal growth factor receptor (EGFR). The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC)...Wikipedia

Manufacturer's Website: Portrazza

Average retail cost: $4,300/month

NERLYNX is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early-stage HER2‑overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.

Manufacturer's Website: Nerlynx

Average retail cost: $5,700/month

Gefitinib (trade name Iressa) is a drug used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR... Wikipedia

Manufacturer's Website: Caprelsa                                                                  Average retail cost: $6,550/month

Vandetanib (INN, trade name Caprelsa) is an anti-cancer drug that is used for the treatment of certain tumours of the thyroid gland. It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET-tyrosine kinase...Wikipedia

Manufacturer's Website: Caprelsa

Average retail cost: $6,550/month

Erlotinib hydrochloride (trade name Tarceva) is a drug used to treat non-small cell lung cancer (NSCLC), pancreatic cancer and several other types of cancer. It is a receptor tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR)... Wikipedia

Manufacturer's Website: Tarceva

Average retail cost: $9,000/month

Osimertinib (previously known as mereletinib or AZD9291; trade name Tagrisso) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals – for mutated EGFR cancers... Wikipedia

Manufacturer's Website: Tagrisso

Average retail cost: $14,500/month

Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is distributed under the trade name Erbitux in the U.S. and Canada by the drug company Bristol-Myers Squibb and outside the U.S. and Canada by the drug company Merck KGaA... Wikipedia

Manufacturer's Website: Erbitux

Average retail cost: *

* This prescription is provided by your healthcare provider. It cannot be filled in a pharmacy and may be expensive.

Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans). Panitumumab is manufactured by Amgen and marketed as Vectibix. It was originally developed by Abgenix Inc... Wikipedia

Manufacturer's Website: Vectibix

Average retail cost: *

* This prescription is provided by your healthcare provider. It cannot be filled in a pharmacy and may be expensive.